Cargando…

Quality of life outcomes in two phase 3 trials of setmelanotide in patients with obesity due to LEPR or POMC deficiency

INTRODUCTION: Individuals with proopiomelanocortin (POMC) or leptin receptor (LEPR) deficiency are young and experience severe obesity, hyperphagia, and comorbidities, which can impair quality of life (QOL). METHODS: Two pivotal Phase 3 trials explored the effect of setmelanotide on body weight and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kühnen, Peter, Wabitsch, Martin, von Schnurbein, Julia, Chirila, Costel, Mallya, Usha G., Callahan, Patrick, Gnanasakthy, Ari, Poitou, Christine, Krabusch, Philipp M., Stewart, Murray, Clément, Karine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8817523/ https://www.ncbi.nlm.nih.gov/pubmed/35123544 http://dx.doi.org/10.1186/s13023-022-02186-z

Ejemplares similares

Natural History of Obesity Due to POMC, PCSK1, and LEPR Deficiency and the Impact of Setmelanotide
por: Wabitsch, Martin, et al.
Publicado: (2022)

Understanding the Patient Experience of Hunger and Improved Quality of Life with Setmelanotide Treatment in POMC and LEPR Deficiencies
por: Wabitsch, Martin, et al.
Publicado: (2022)

ODP607 Long-term Efficacy of Setmelanotide in Patients With POMC or LEPR Deficiency Obesity
por: Clément, Karine, et al.
Publicado: (2022)

Timing of Onset of Adverse Events With Setmelanotide, an MC4R Agonist, in Patients With Severe Obesity Due to LEPR or POMC Deficiency
por: Clément, Karine, et al.
Publicado: (2021)

Quality of life improvements following one year of setmelanotide in children and adult patients with Bardet–Biedl syndrome: phase 3 trial results
por: Forsythe, Elizabeth, et al.
Publicado: (2023)

Beneficial Effects of Setmelanotide in a 5-Year-Old Boy With POMC Deficiency and on His Caregivers
por: Dubern, Beatrice, et al.
Publicado: (2023)

OR10-1 Body Mass Index and Weight Reductions in Patients With Obesity Due to Heterozygous Variants in POMC, PCSK1, and LEPR After 1 Year of Setmelanotide
por: Farooqi, Sadaf, et al.
Publicado: (2022)

RF24 | PSUN96 Setmelanotide in Patients With Heterozygous POMC, LEPR, SRC1, or SH2B1 Obesity: Design of EMANATE – A Placebo-Controlled Phase 3 Trial
por: Wabitsch, Martin, et al.
Publicado: (2022)

A Phase 3 Trial in Participants With Obesity Due to Bardet-Biedl Syndrome or Alström Syndrome: Efficacy and Safety of the Melanocortin 4 Receptor Agonist Setmelanotide
por: Haws, Robert, et al.
Publicado: (2021)

Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds
por: Strand, Vibeke, et al.
Publicado: (2014)

Interview-Based Patient- and Caregiver-Reported Experiences of Hunger and Improved Quality of Life with Setmelanotide Treatment in Bardet-Biedl Syndrome
por: Ervin, Claire, et al.
Publicado: (2023)

A Setmelanotide-like Effect at MC4R Is Achieved by MC4R Dimer Separation
por: Reininghaus, Nanina, et al.
Publicado: (2022)

ODP606 Long-term Efficacy of Setmelanotide in Patients With Bardet-Biedl Syndrome
por: Argente, Jesús, et al.
Publicado: (2022)

IGF2, LEPR, POMC, PPARG, and PPARGC1 gene variants are associated with obesity-related risk phenotypes in Brazilian children and adolescents
por: Queiroz, E.M., et al.
Publicado: (2015)

Effect of setmelanotide, a melanocortin‐4 receptor agonist, on obesity in Bardet‐Biedl syndrome
por: Haws, Robert, et al.
Publicado: (2020)

Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency
por: Collet, Tinh-Hai, et al.
Publicado: (2017)

Structures of active melanocortin-4 receptor–Gs-protein complexes with NDP-α-MSH and setmelanotide
por: Heyder, Nicolas A., et al.
Publicado: (2021)

The efficacy and safety of setmelanotide in individuals with Bardet-Biedl syndrome or Alström syndrome: Phase 3 trial design
por: Haws, Robert M., et al.
Publicado: (2021)

La Lepre
Publicado: (1934)

Osteogenesis Imperfecta Due to Compound Heterozygosity for the LEPRE1 Gene
por: Moul, Adrienne, et al.
Publicado: (2013)

RF24 | PSUN91 Body Mass Index and Weight Reduction in Patients With SH2B1 Genetic Variant Obesity After One Year of Setmelanotide
por: Argente, Jesús, et al.
Publicado: (2022)

Restoration of Lepr in β cells of Lepr null mice does not prevent hyperinsulinemia and hyperglycemia
por: D'souza, Anna M., et al.
Publicado: (2017)

Proopiomelanocortin (POMC) and psychodermatology
por: Millington, George W. M., et al.
Publicado: (2023)

Setmelanotide: a promising advancement for pediatric patients with rare forms of genetic obesity
por: Trapp, Christine M., et al.
Publicado: (2023)

Obesity, POMC, and POMC-processing Enzymes: Surprising Results From Animal Models
por: Lindberg, Iris, et al.
Publicado: (2021)

Monogenic forms of childhood obesity due to mutations in the leptin gene
por: Funcke, Jan-Bernd, et al.
Publicado: (2014)

FRI082 Impact Of Setmelanotide On Metabolic Parameters And Vital Signs In Patients With Hypothalamic Obesity
por: Jennifer Abuzzahab, M, et al.
Publicado: (2023)

Characterization of a new animal model of metabolic syndrome: the DahlS.Z-Lepr(fa)/Lepr(fa) rat
por: Hattori, T, et al.
Publicado: (2011)

SAT656 Weight Reduction After 6 Months Of Setmelanotide Treatment In Patients With Hypothalamic Obesity
por: Roth, Christian L, et al.
Publicado: (2023)

Selective Restoration of Pomc Expression in Glutamatergic POMC Neurons: Evidence for a Dynamic Hypothalamic Neurotransmitter Network
por: Jones, Graham L., et al.
Publicado: (2019)

PREMATURE CARDIAC SENESCENCE IN DahlS.Z-Lepr(fa)/Lepr(fa) RATS AS A NEW ANIMAL MODEL OF METABOLIC SYNDROME
por: TAKAHASHI, KEIJI, et al.
Publicado: (2014)

Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?
por: Ryan, Donna H.
Publicado: (2021)

Adiponectin potentiates the acute effects of leptin in arcuate Pomc neurons
por: Sun, Jia, et al.
Publicado: (2016)

Metformin Suppresses Diethylnitrosamine-Induced Liver Tumorigenesis in Obese and Diabetic C57BL/KsJ-+Lepr(db)/+Lepr(db) Mice
por: Ohno, Tomohiko, et al.
Publicado: (2015)

The role of proopiomelanocortin (POMC) neurones in feeding behaviour
por: Millington, George WM
Publicado: (2007)

PERK in POMC neurons connects celastrol with metabolism
por: He, Zhenyan, et al.
Publicado: (2021)

The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide
por: Akinci, Baris, et al.
Publicado: (2020)

OR16-03 Metabolic Effects Of Hypothalamic Pomc Neurons Generated Postnatally From Tanycytes On A Pomc Null Genetic Background
por: Gahlot, Surbhi, et al.
Publicado: (2020)

Diagnostic and therapeutic odyssey of two patients with compound heterozygous leptin receptor deficiency
por: Zorn, Stefanie, et al.
Publicado: (2020)

Lower Circulating Leptin Levels Are Related to Non-Alcoholic Fatty Liver Disease in Children With Obesity
por: Brandt, Stephanie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_83i2qq5jfqoidcq3ii8or7k8gi